CVS Health® is committed to advancing the availability of groundbreaking treatments like gene therapies and genetically modified cellular therapies. These innovative treatments can treat and potentially cure genetic disorders, including sickle cell disease, an illness the medical community once considered incurable.
Our latest report is co-authored by Sree Chaguturu, MD, Executive Vice President and Chief Medical Officer, CVS Health; Joanne Armstrong, MD, MPH, Vice President and Chief Medical Officer, Women’s Health and Genomics, CVS Health; and Michelle Gourdine, MD, Senior Vice President, CVS Health, and Chief Medical Officer, CVS Caremark®. It explores the science behind these advanced therapies and provides insights into how the treatments work, their administration processes and the types of diseases they can treat.
The report also discusses the challenges associated with the high costs and the strategies employed by health care providers and insurers to make these therapies accessible to more patients. Through our commitment to innovation and patient care, CVS Health is helping to make these life-changing treatments accessible to more people.
